0.95Open1.05Pre Close1 Volume542 Open Interest260.00Strike Price95.00Turnover43.83%IV11.38%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.95Extrinsic Value100Contract SizeAmericanOptions Type0.1083Delta0.0099Gamma246.61Leverage Ratio-0.1431Theta0.0082Rho26.70Eff Leverage0.0799Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet